Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Moritake

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Pediatrics International : Official Journal of the Japan Pediatric Society|August 4, 2017
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemiaHideki Nakayama, Daisuke Tomizawa, Shiro Tanaka, et al.
Haematologica|May 13, 2014
Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemiaHirotoshi Sakaguchi, Nobuhiro Nishio, Asahito Hama, et al.
Blood|August 7, 2004
Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantationYoshiyuki Kosaka, Katsuyoshi Koh, Naoko Kinukawa, et al.
International Journal of Hematology|June 26, 2014
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocolHideki Nakayama, Ken Tabuchi, Akio Tawa, et al.
British Journal of Haematology|April 28, 2020
Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 studyTakahiro Aoki, Hiroyuki Takahashi, Shiro Tanaka, et al.
International Journal of Hematology|September 27, 2013
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupDaisuke Tomizawa, Akio Tawa, Tomoyuki Watanabe, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2026
Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndromeAkari Nakamura-Utsunomiya, Kosei Hasegawa, Taisuke Ono, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|August 18, 2015
Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST)Takuya Fujimoto, Tooru Andoh, Tamotsu Sudo, et al.
Pediatric Blood & Cancer|September 5, 2020
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)Daiichiro Hasegawa, Akio Tawa, Daisuke Tomizawa, et al.
Pediatric Blood & Cancer|October 21, 2015
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in JapanTakashi Taga, Tomoyuki Watanabe, Daisuke Tomizawa, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Pediatrics International : Official Journal of the Japan Pediatric Society|August 4, 2017
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemiaHideki Nakayama, Daisuke Tomizawa, Shiro Tanaka, et al.
Haematologica|May 13, 2014
Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemiaHirotoshi Sakaguchi, Nobuhiro Nishio, Asahito Hama, et al.
Blood|August 7, 2004
Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantationYoshiyuki Kosaka, Katsuyoshi Koh, Naoko Kinukawa, et al.
International Journal of Hematology|June 26, 2014
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocolHideki Nakayama, Ken Tabuchi, Akio Tawa, et al.
British Journal of Haematology|April 28, 2020
Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 studyTakahiro Aoki, Hiroyuki Takahashi, Shiro Tanaka, et al.
International Journal of Hematology|September 27, 2013
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupDaisuke Tomizawa, Akio Tawa, Tomoyuki Watanabe, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2026
Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndromeAkari Nakamura-Utsunomiya, Kosei Hasegawa, Taisuke Ono, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|August 18, 2015
Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST)Takuya Fujimoto, Tooru Andoh, Tamotsu Sudo, et al.
Pediatric Blood & Cancer|September 5, 2020
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)Daiichiro Hasegawa, Akio Tawa, Daisuke Tomizawa, et al.
Pediatric Blood & Cancer|October 21, 2015
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in JapanTakashi Taga, Tomoyuki Watanabe, Daisuke Tomizawa, et al.
Pageof 12